Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 95%
filed 2026-09-03
Item 5.02
Byrna Technologies appointed Matthew McBrady, Ph.D. to its Board of Directors, effective August 29, 2026. Dr. McBrady brings substantial experience from his tenure on Axon Enterprise's board (2001–2014, 2016–2026), where he chaired multiple committees, combined with CFO experience at GoBrands and hedge fund/private equity investment expertise. The board was expanded from seven to eight members as part of a planned board refreshment strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-03
Item 5.02
Wil W. Osborn was appointed as President and Chief Executive Officer of Federal Home Loan Bank of Des Moines, effective October 1, 2026, following a comprehensive succession planning process. The appointment includes compensation of $900,000 annual salary plus incentive awards up to 100% of base salary.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-03
Item 5.02
The disclosure centers on the appointment of Richard James as Controller and Chief Accounting Officer effective April 1, 2027, following Matt Simmons' announced retirement. While both a departure and appointment occur, the filing emphasizes James's appointment with detailed background and qualifications, making the appointment the principal disclosed action. The Controller/CAO role is a named executive officer position material to investors assessing financial reporting oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-03
Item 5.02
The filing discloses both a departure (Sofia Chernylo as Senior Vice President and Chief Accounting Officer) and an appointment (Matthew Fennewald to the same role). While both events occur, the principal focus and substantive disclosure centers on Fennewald's appointment, including his detailed background, prior roles at the Company, professional credentials (CPA), and prior experience at PwC and Crowe Horwath. The appointment of a principal accounting officer is material to investors assessing the registrant's financial reporting controls and leadership continuity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-03
Item 5.02
David McAvoy was appointed as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary on August 31, 2026, bringing 30+ years of biopharmaceutical legal leadership experience from roles at Eli Lilly, Endocyte, Brickell Biotech, and Teva to support the Company through VAX-31's development and anticipated commercialization.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-03
Item 5.02
UiPath announced three executive appointments: Hitesh Ramani as Chief Financial Officer (promoted from Deputy CFO and Chief Accounting Officer), Brad Brubaker as Chief Legal & Administrative Officer (expanded from Chief Legal Officer), and Yazdi Bagli as a new independent board member. Ashim Gupta transitioned from CFO to Chief Operating Officer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-03
Item 5.02
The Board approved the appointment of Tigran Sinanyan as Chief Financial Officer and Treasurer, effective October 1, 2026. Sinanyan, who previously served as CFO from 2015–2021 and has been SVP Finance since July 2025, will receive a base salary of $475,000, target bonus of 70% of base salary, and an RSU award of $252,100, along with severance and change-of-control protections.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-03
Item 5.02
The filing discloses both a director departure (Paul Krause's resignation effective August 31, 2026) and a director appointment (Matt Ryan appointed to the Board effective September 1, 2026). While both events are present, the appointment of Matt Ryan is the principal forward-looking action and receives substantive disclosure including his current role as Chief Marketing and Technology Officer of Harley-Davidson, Inc., making the appointment the more salient event. Board composition changes are material to investors assessing governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
The filing discloses the appointment of five Executive Vice Presidents effective September 1, 2026: Joseph M. McFarland III (Pro and Home Services), Quonta D. Vance (Stores), Seemantini Godbole (Chief Information and AI Officer), Adam D. Filipponi (Strategy and Business Development), and Jennifer E. Wilson (Chief Marketing Officer). The Company explicitly states these appointments are "designed to strengthen the execution of our Total Home strategy and position Lowe's for our next phase of growth," indicating material strategic reorganization affecting senior leadership and accountability structures.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-09-02
EX-99.1
Ms. Li Lu has been appointed as Joint Company Secretary, Authorized Representative, and Chief Financial Officer effective September 2, 2026, replacing Ms. Qu Cong who resigned. While the announcement discloses both a departure and an appointment, the principal disclosed action is the appointment of Ms. Li to these officer roles. The appointment is material because it involves a named executive (CFO) and requires a regulatory waiver from the Hong Kong Stock Exchange due to Ms. Li's lack of formal company secretary qualifications, indicating governance significance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 8.01
Angela M.W. Kelley has been appointed as Executive Vice President, General Counsel and Corporate Secretary, effective October 13, 2026, succeeding Randall J. Erickson.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 7.01
Kroger announced the appointment of Mark Ibbotson as Executive Vice President and Chief Store Operations Officer, effective September 14, 2026. This is a named executive appointment to a senior leadership role overseeing critical store operations and digital transformation initiatives. The press release emphasizes his extensive retail operations experience at Walmart and Asda, making this a material executive appointment that would affect investor assessment of the company's operational leadership.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-02
The 6-K discloses the appointment of Mr. Bo Wang as Chief Financial Officer effective September 1, 2026, following the resignation of Mr. Mengnan Wang. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite role (CFO). Mr. Bo Wang's qualifications—CPA in China, 10+ years in auditing and accounting, prior experience at Arthur Andersen and as financial controller—are detailed, and the Board's formal recommendation and appointment are documented. This is material to investors as it affects the registrant's financial leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
The filing discloses the appointment of Clay Ritchey as Chief Executive Officer and Board member, effective September 8, 2026. While the section also mentions Kevin Coop's departure as CEO, the principal disclosed action centers on the new CEO appointment with detailed employment terms including $500,000 base salary, 87.5% target bonus, and $4,000,000 in new hire equity awards. This is a material executive leadership change affecting investor assessment of company direction and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
The Board appointed James E. Olsson as Executive Vice President, Chief Growth Officer effective September 6, 2026, with oversight of direct businesses, retail stores, merchandising, planning, global sourcing, and brand strategy. His compensation package includes a base salary of $475,000, an RSU grant of $250,000, an annual bonus target of 60%, and LTIP participation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-09-02
Item 5.02
Aric Chang was appointed as Chief Financial Officer of American Healthcare REIT, Inc., effective October 1, 2026, succeeding Brian S. Peay who is retiring after 10 years in the role. Chang brings extensive REIT finance and capital allocation experience from Public Storage, with compensation terms including a $500,000 base salary, 100% target bonus, $1,000,000 long-term incentive award, and $310,000 sign-on bonus.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
On August 27, 2026, Steven Tannenbaum, William J. Liquori, and William Denkin were appointed to the board of directors in connection with the IPO, with assignments to the Audit and Compensation committees. The appointments establish the company's independent director governance structure at the time of its public offering.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
The filing discloses the appointment of three new independent directors (Mark Schwartz, Kimi L. Ellen, and Dante W. Robinson) to Solidion's Board, increasing board size from four to seven members. The appointments are material as they strengthen the company's financial and governance expertise, and critically, the Audit Committee appointments restore Nasdaq Rule 5605(c)(2)(A) compliance, which the company had previously lost. This is a significant governance event affecting board composition and committee structure.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-02
The filing discloses that the Board of Directors approved the election of Benjamin Steinbruch as Chairman of the Board and that Fabio Schvartsman will assume the position of Chief Executive Officer (CEO) effective September 3, 2026. These are material executive appointments at the highest levels of the company. The disclosure is labeled "MATERIAL FACT" and filed as a 6-K, indicating the registrant itself considers this material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-02
Item 5.02
The filing discloses both a resignation (Vincent J. Arnone stepping down as Chairman effective September 15, 2026) and an appointment (Sharon L. Jones elected as Chairman effective September 16, 2026). While both events occur, the principal action centers on the appointment of a new Chairman to fill the vacancy, making exec_appointment the most salient classification. The change in board leadership is material to investors assessing governance and strategic direction.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-09-02
The 6-K discloses the appointment of three new directors to Basel Medical Group's board: Mr. Yang Xinwen, Ms. Cao Juan, and Mr. Frederick Hong. While two incumbent directors (Fung Keng Leong and Tan Boon Chye) departed, the principal disclosed action is the addition of three new board members with detailed biographical information and expected contributions to governance and strategic leadership. This constitutes a material executive appointment event affecting board composition and governance capabilities.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-02
Item 5.02
Philip J. Boeckman is appointed as Chief Legal Officer effective October 1, 2026, a named executive officer role overseeing legal functions. While Renee L. Wilm's transition to Senior Advisor represents a departure from her prior role, the principal disclosed action centers on the appointment of Boeckman to a material C-suite position. The detailed background on Boeckman's qualifications and experience underscores the significance of this appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
The filing discloses the appointment of Anish K. Shah as Vice President & Controller and principal accounting officer of Murphy USA, effective September 1, 2026. While the disclosure includes compensatory details (base salary of $360,000, bonus and equity targets, and a $25,000 sign-on bonus), the principal disclosed action is the appointment of a named executive to a key accounting and financial reporting role. This is material to investors as the principal accounting officer is responsible for financial statement preparation and internal controls.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-09-02
Item 5.02
Jeff Epstein, former Oracle CFO and current Bessemer Venture Partner with board experience at Autodesk, Twilio, and AvePoint, was appointed to Zoom's Board of Directors effective August 31, 2026, and assigned to the Audit Committee. Jonathan Chadwick's resignation from the board was also disclosed in connection with this transition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
Dave Hulays was appointed as Senior Vice President and Chief Financial Officer of The Hershey Company effective September 2, 2026, succeeding Steven E. Voskuil who transitioned to Senior Vice President, Strategic Projects.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-02
Ian Tyler has been appointed as Chair of BP following an extensive search process, assuming the role immediately after serving as Interim Chair since May 2026. The appointment of a Chair is a material governance event affecting the registrant's leadership structure and board composition, and the disclosure explicitly announces this as a principal corporate action.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
The filing discloses the appointment of Anthony Armstrong as a director of Coinbase Global, Inc., effective immediately following Board approval on September 1, 2026. The Board increased its size from nine to ten directors specifically to accommodate this appointment. While the disclosure includes standard compensation and indemnification details, the principal disclosed action is the appointment of a new director to the Board and assignment to the Audit and Compliance Committee, making this an executive appointment event material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-02
Item 5.02
The filing discloses the appointment of Philip J. Boeckman as Chief Legal Officer effective October 1, 2026, with detailed background on his qualifications and prior role as Partner at Cravath, Swaine & Moore LLP. While the filing also mentions Renee L. Wilm's transition to Senior Advisor, the principal disclosed action centers on the appointment of a new Chief Legal Officer, a named executive officer role. This is material to investors as it reflects a change in senior legal leadership and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-02
Item 5.02
Philip J. Boeckman is appointed as Chief Legal Officer effective October 1, 2026, a named executive officer role. While Renee L. Wilm's transition to Senior Advisor represents a departure from her prior role, the principal disclosed action centers on the appointment of Boeckman to a key C-suite position. The detailed background on Boeckman's qualifications and experience at Cravath emphasizes the significance of this appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
William W. Weatherford was appointed as a director of Raymond James Financial, Inc., effective December 15, 2026, and was also appointed to the Audit Committee and Risk Committee. The Board determined he is independent.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
Jonathan Poole was appointed as Executive Vice President and Chief Financial Officer effective January 1, 2027. While the disclosure also mentions Charles F. Wagner, Jr. ceasing to serve as CFO, the principal action disclosed is Poole's appointment to a C-suite financial role at a major pharmaceutical company. The filing details his compensation arrangements ($750,000 base salary, 90% target bonus) and change-of-control protections, which are typical components of executive appointment disclosures under Item 5.02(a) and (e).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
Gregory B. Braca, a seasoned financial executive with 40+ years of experience and former president and CEO of TD Bank, has been appointed to Mid Penn Bancorp's Board of Directors effective September 16, 2026, with assignment to the Audit, Compensation, and Risk Committees.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
The filing discloses the appointment of Gael Touya as a director effective September 1, 2026, following his appointment as President and Chief Executive Officer (previously disclosed on March 17, 2026). The principal action is Touya taking on the director role, making this an executive appointment. This is material as it involves a change in board composition and reflects the CEO succession that occurred on the same date.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-01
The 6-K discloses the appointment of Yaron Eldad as Chief Financial Officer of Freightos Limited, effective September 1, 2026. The filing provides detailed background on his prior CFO roles at Evogene Ltd. and Yamba Group International, Ltd., as well as his educational credentials and current board service. Appointment of a CFO is a material executive appointment that would affect a reasonable investor's assessment of the registrant's leadership and financial management.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
An Nuyttens has been appointed President of Mohawk's Flooring Rest of the World segment, effective mid-October 2026. The appointment emphasizes her 30+ years of international leadership experience and the strategic importance of this segment to the company's long-term growth.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-09-01
EX-99.1
Søren Steenberg Jensen assumed the role of Chief Executive Officer on 1 September 2026, succeeding Mikael Øpstun Skov. The company stated the appointment will not change strategy or operating mode.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-01
EX-99.2
Mikael Øpstun Skov was appointed as a Director of Hafnia Limited, effective from the Extraordinary General Meeting on 23 September 2026, following his departure as Chief Executive Officer. The Nomination Committee emphasized his instrumental role in establishing the Company's strategic direction and extensive institutional knowledge.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
The Board of Directors appointed Zane Nielsen as Chief Accounting Officer and Corporate Controller effective September 1, 2026, replacing Richard Hoffman in the principal accounting officer role. This is a material executive appointment to a key financial leadership position, supported by detailed biographical information and compensation terms ($350,000 base salary, 50% bonus target, 60% LTI target).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
Marc Elia, the Company's Chairman, was appointed as Chief Executive Officer effective August 30, 2026, assuming the principal executive officer role previously held by William Duke, Jr. The appointment includes compensatory arrangements including a base salary of $750,000, target bonus of 70%, stock option grant of 10.7 million shares, and sign-on bonus of $500,000.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-01
The 6-K announces the appointment of Andreas Tolpeit as Chief Financial Officer and member of the executive committee, effective September 1, 2026. While the filing also mentions the departure of Jany Fruytier as CFO, the principal disclosed action is Tolpeit's appointment to a named executive officer role. CFO appointments are material to investors as they affect financial oversight and strategy execution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
Robert Ragusa was appointed to the Board of Directors effective September 1, 2026, and simultaneously appointed to three Board committees (Audit, Compensation, and Nominating and Corporate Governance). The disclosure centers on the appointment action itself, with compensation details provided as a secondary matter under the Non-Employee Director Compensation Policy. Board appointments are material governance events affecting the registrant's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-01
Item 5.02
The filing discloses multiple executive leadership changes effective September 1, 2026: M. Sean Covey's transition to Chief Product Officer (a promotion from President, Education Division), John Buchanan's appointment as Executive Vice President, Education (new hire), and Adam Sherman's appointment to succeed Colleen Dom as Executive Vice President, Operations (effective June 1, 2027). While the section also includes Colleen Dom's retirement announcement, the primary focus and most material event is the appointment of executives to key leadership roles, particularly the new Chief Product Officer position and the external hire of an EVP. These changes to senior management structure are material to investors assessing the company's leadership continuity and strategic direction.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-01
The 6-K announces the appointment of Mr. Xiaohui Li as co-executive officer of Jianzhi Education Technology Group Company Limited, effective September 1, 2026. The disclosure provides his background, prior roles at Zhiyi Eastern Securities and Shenzhen Hongying Capital Management, and educational credentials. This is a clear executive appointment that would affect a reasonable investor's assessment of the company's leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 7.01
Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S. as Chief Medical Officer, effective September 1, 2026. Dr. Charlton brings extensive experience in rare disease and pediatric drug development and will lead the company's planned SOTERIA Phase 2 trial initiation in Q4 2026, making this a material appointment for a clinical-stage biotech company on the eve of a pivotal trial launch.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
Greenlight Capital Re appointed John Welch as an independent director effective September 1, 2026, and simultaneously appointed him to three board committees (Audit, Compensation, and Underwriting). The company also elected Ariel Warszawski as a director at its July 28, 2026 Annual General Meeting. Both appointments strengthen the board's governance and oversight capabilities.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-01
Item 5.02
The filing discloses two executive changes: the retirement of J. Stanley Fredrick as Chairman and Board member effective September 1, 2026, and the appointment of Robert Toth as Chairman effective the same date. While both a departure and appointment occur, the principal disclosed action centers on Toth's appointment to the Chairman role, which is the forward-looking governance change. The filing emphasizes Toth's qualifications, prior board service, and compensation structure as Chairman, making the appointment the salient event. Fredrick's retirement is presented as context for the transition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-01
Item 5.02
James Bligh was appointed Chief Executive Officer effective August 31, 2026, with an employment agreement providing $600,000 annual base salary and 50% target bonus. While the section also discloses Dr. Andrew Regan's simultaneous resignation as CEO, the principal disclosed action centers on Bligh's appointment to the chief executive role, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-01
The filing discloses the appointment of two key executives: Josua Oosthuizen as CEO (effective July 31, 2026) and Pieter Scholtz as CFO (effective August 8, 2026), both under two-year employment agreements with specified compensation. While Item 5.02 also covers compensatory arrangements, the principal disclosed action centers on the appointment of these officers to new roles, particularly the CEO appointment which is material to investor assessment of company leadership and strategy execution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-01
Item 5.02
Dr. Kim Reid was appointed as a director and audit committee member, while John Bientjes resigned as director and audit committee chair, and Davis Fynn was elevated to audit committee chair. The filing centers on Dr. Reid's appointment and her specialized scientific and governance expertise.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-01
The filing discloses both the resignation of Co-CEO and Chairman Sheng-Yih Chang (effective September 1, 2026) and the appointment of Kewei Huang as CEO and Chairman (also effective September 1, 2026). While both events occur, the appointment is the principal forward-looking action and receives more substantive disclosure, including details of the Executive Employment Agreement with $60,000 annual base compensation. The appointment of a new CEO and Chairman to lead the company is material to investors.
View raw filing on EDGAR →